Literature DB >> 9830458

Options for artificial nutrition of cancer patients.

S Pille1, D Böhmer.   

Abstract

BACKGROUND: Until today, 25 to 50% of ill or severely disabled patients show qualitative or quantitative nutritional deficits which can lead to a disease aggravation and thus may be a limiting factor in oncologic treatment strategies. Therefore the various options for artificial nutrition should be used according to strict indications. These are whenever the patient is not able to eat (e.g. acute mucositis), does not want to eat (e.g. nausea Grade 3 to 4) or is not allowed to eat (e.g. pancreatitis).
METHODS: The principle is to apply as much as possible enteral feeding because of its advantages. Enteral nutrition is more physiological, safer and more reasonable. A prerequisite for an adequate feeding is the optimal nutrient composition and detection of patient's individual nutritional status. Numerous options for the adequate application technique of nutritional support are available: 1. oral diets with commercially available supplement drinks; 2. the pump-assisted application by using nasal or percutaneous probes bears many advantages when some important basic rules are not neglected to guarantee a complication free course, e.g. the choice of right nutrients for the right indications, the control of the tube-position and a smooth build-up of the application; 3. peripheral or central venous application is necessary if contraindications prevent the use of enteral nutrition (e.g. ileus, pancreatitis). The following parameters have to be taken into account when generating a parenteral nutrition programme: diagnosis, the present status of the patient's disease, the actual body weight and ideal weight, the laboratory test results, the need of total energy of nutrients in detail and of fluid and electrolytes.
CONCLUSIONS: The prevention of malnutrition by adequate therapies for patients with anorexia or cachexia may contribute to a reduction of morbidity and mortality in cancer therapy. There is also a substantial impact of malnutrition on the outcome of anti cancer therapies. Finally a large decrease in health care costs may result from a prevention of cachexia.

Entities:  

Mesh:

Year:  1998        PMID: 9830458

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  12 in total

1.  Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.

Authors:  Wendy M Kersemaekers; Thijs van Iersel; Ulla Nassander; Edward O'Mara; Hetty Waskin; Maria Caceres; Marlou L P S van Iersel
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

2.  Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.

Authors:  Wendy M Kersemaekers; Peter Dogterom; Jialin Xu; Eugene E Marcantonio; Rik de Greef; Hetty Waskin; Marlou L P S van Iersel
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

3.  Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.

Authors:  Gopal Krishna; Lei Ma; Monika Martinho; Edward O'Mara
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

4.  Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.

Authors:  Oliver A Cornely; David Helfgott; Amelia Langston; Werner Heinz; Jörg-Janne Vehreschild; Maria J G T Vehreschild; Gopal Krishna; Lei Ma; Susan Huyck; Michael C McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

5.  Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Authors:  Rafael F Duarte; Javier López-Jiménez; Oliver A Cornely; Michel Laverdiere; David Helfgott; Shariq Haider; Pranatharthi Chandrasekar; Amelia Langston; John Perfect; Lei Ma; Marlou L P S van Iersel; Nancy Connelly; Nicholas Kartsonis; Hetty Waskin
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

6.  Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.

Authors:  Walter K Kraft; Peter S Chang; Marlou L P S van Iersel; Hetty Waskin; Gopal Krishna; Wendy M Kersemaekers
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

7.  Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.

Authors:  Kaiyan Liu; Depei Wu; Junmin Li; Hu Chen; Hongmei Ning; Ting Zhao; Haiping Dai; Li Chen; Eric Mangin; Gregory A Winchell; Hetty Waskin; Jun Jiang; Yanping Qiu; Xu Min Zhao
Journal:  Adv Ther       Date:  2020-04-22       Impact factor: 3.845

8.  Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers.

Authors:  Gopal Krishna; Lei Ma; Donna Vickery; Xin Yu; Irene Wu; Edward Power; Eric Beresford; Steven Komjathy
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

9.  Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.

Authors:  Elizabeth S Dodds Ashley; Jay B Varkey; Gopal Krishna; Donna Vickery; Lei Ma; Xin Yu; Darshana Malavade; Megan Goodwin; John R Perfect; Eddie Power
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

10.  Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

Authors:  Johan Maertens; Oliver A Cornely; Andrew J Ullmann; Werner J Heinz; Gopal Krishna; Hernando Patino; Maria Caceres; Nicholas Kartsonis; Hetty Waskin; Michael N Robertson
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.